Cellectis S.A. (CLLS)

1.6300 -0.0700 (-4.12%) As of 10:54AM EDT. Market open.

Cellectis S.A.

8, rue de la Croix Jarry
Paris 75013
France
33 1 81 69 16 00
https://www.cellectis.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 231

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Andre Choulika Ph.D.	Co-Founder, CEO & Director	744.02k	N/A	1965
Dr. David J. D. Sourdive Ph.D.	Deputy CEO, Exec. VP of CMC & Manufacturing and Directorr	528.92k	N/A	1967
Dr. Bing C. Wang M.B.A., Ph.D.	Chief Financial Officer	N/A	N/A	1977
Valerie Cros	Principal Financial Officer & Principal Accounting Officer	N/A	N/A	N/A
Mr. Jean Charles Epinat	Chief Technological Officer	N/A	N/A	N/A
Dr. Philippe Duchateau Ph.D.	Chief Scientific Officer	N/A	N/A	1963
Mr. Stephan Reynier M.Sc., MSc	Chief Regulatory & Pharmaceutical Compliance Officer	N/A	N/A	1969
Ms. Marie-Bleuenn Terrier	Gen. Counsel & Sec. of the Board of Directors	N/A	N/A	1982
Pascalyne Wilson	Director of Communications	N/A	N/A	N/A
Ms. Kyung Nam-Wortman	Exec. VP & Chief HR Officer	N/A	N/A	1970

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia Therapeutics. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Corporate governance

Cellectis S.A.’s ISS governance QualityScore as of 1 September 2023 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 10; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.